Bone Biologics (BBLG) Interest Expenses (2014 - 2025)
Bone Biologics (BBLG) posted quarterly Interest Expenses of $88334.0 for Q4 2025, up 1.61% year-over-year from $86931.0 in Q4 2024, and down 63.54% quarter-over-quarter from $242297.0 in Q3 2025.
Powered by 
Analysis
Bone Biologics (BBLG) Interest Expenses (2014 - 2025) Analysis & Trends
Bone Biologics (BBLG) has reported Interest Expenses for 13 consecutive years, with $88334.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Interest Expenses rose 1.61% year-over-year to $88334.0; the TTM figure through Dec 2025 stood at $330631.0 (up 280.34% YoY), while the FY2025 annual figure was $24.8 million, up 14.43% from the prior year.
- Interest Expenses fell to $88334.0 in Q4 2025 per BBLG's latest filing, from $242297.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $20.4 million in Q4 2023 and bottomed at -$778295.0 in Q4 2021.
- Historically, Interest Expenses has averaged $3.2 million across 5 years, with a median of $88334.0 in 2025.
- Annual changes were most pronounced in 2021 — Interest Expenses tumbled 414.74% — and 2022, when it jumped 2714.95%.
- Bone Biologics' Interest Expenses stood at -$778295.0 in 2021, then surged by 2714.95% to $20.4 million in 2022, then rose by 0.29% to $20.4 million in 2023, then sank by 99.57% to $86931.0 in 2024, then gained by 1.61% to $88334.0 in 2025.
- Business Quant data shows BBLG's Interest Expenses at $88334.0 in Q4 2025, $242297.0 in Q3 2025, and $86931.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Bone Biologics | 1.00 Mn | 1.00 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 88,334.00 |
| Sep 30, 2025 | 242,297.00 |
| Dec 31, 2024 | 86,931.00 |
| Sep 30, 2024 | 290,836.00 |
| Dec 31, 2021 | 14,755.00 |
| Sep 30, 2021 | 279,514.00 |
| Jun 30, 2021 | 260,017.00 |
| Mar 31, 2021 | 250,823.00 |
| Dec 31, 2020 | 247,279.00 |
| Sep 30, 2020 | 248,226.00 |
| Jun 30, 2020 | 247,321.00 |
| Mar 31, 2020 | 255,250.00 |
| Dec 31, 2019 | 253,554.00 |
| Sep 30, 2019 | 260,070.00 |
| Jun 30, 2019 | 244,695.00 |
| Mar 31, 2019 | 217,456.00 |
| Dec 31, 2018 | 231,760.00 |
| Sep 30, 2018 | 238,234.00 |
| Jun 30, 2018 | 401,576.00 |
| Mar 31, 2018 | 357,917.00 |